Alumni Ventures Group
Alumni Ventures Group is a venture capital firm based in Manchester, New Hampshire, with offices across North America. It provides access to venture investing for individual accredited investors, particularly alumni networks, by offering diversified portfolios of venture opportunities and allowing members to invest alongside fellow alumni in ventures led by peers. The firm backs early-stage and later-stage opportunities across technology, consumer, healthcare, financial services, and other sectors, with a sector- and geography-agnostic approach. It typically invests between $10,000 and $3 million per deal and emphasizes the involvement of alumni connections and an institutional lead investor in opportunities. Alumni Ventures also offers focused funds to broaden participation, enabling accredited investors to access venture portfolios diversified by type, sector, stage, and geography. The model aims to democratize access to venture capital while maintaining rigorous selection standards through alumni networks.
Top Sectors
Top Regions
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Nuclear Energy
X-energy
Series C in 2024
X-energy is a developer of advanced modular nuclear reactors and fuel technology for clean energy generation. The company manufactures fuel that seals uranium particles in a protective coating, making meltdown impossible. It develops safe and efficient reactors and proprietary fuel to deliver reliable, zero-carbon, affordable energy to people worldwide. The simplified, modular, and high-temperature gas reactor design expands applications and markets for the deployment of nuclear technology.
X-energy
Series B in 2021
X-energy is a developer of advanced modular nuclear reactors and fuel technology for clean energy generation. The company manufactures fuel that seals uranium particles in a protective coating, making meltdown impossible. It develops safe and efficient reactors and proprietary fuel to deliver reliable, zero-carbon, affordable energy to people worldwide. The simplified, modular, and high-temperature gas reactor design expands applications and markets for the deployment of nuclear technology.
SHINE
Series C in 2021
SHINE develops and deploys fusion-based technology to produce medical isotopes and neutron sources. Its processes generate molybdenum-99, a precursor to technetium-99m used in diagnostic imaging, and lutetium-177 for diagnostic and therapeutic use, along with iodine-131 and iodine-125 for thyroid treatment and brachytherapy, and xenon-133 for lung and brain imaging. The company’s systems also provide neutron sources for industrial imaging, radiation-effects testing, and fusion materials research. In addition to medical isotopes, SHINE aims to recycle nuclear waste and advance fusion power as a source of clean energy. The business serves health care and industrial customers worldwide. SHINE is based in Janesville, Wisconsin, with an office in Alkmaar, Netherlands.
SHINE
Venture Round in 2020
SHINE develops and deploys fusion-based technology to produce medical isotopes and neutron sources. Its processes generate molybdenum-99, a precursor to technetium-99m used in diagnostic imaging, and lutetium-177 for diagnostic and therapeutic use, along with iodine-131 and iodine-125 for thyroid treatment and brachytherapy, and xenon-133 for lung and brain imaging. The company’s systems also provide neutron sources for industrial imaging, radiation-effects testing, and fusion materials research. In addition to medical isotopes, SHINE aims to recycle nuclear waste and advance fusion power as a source of clean energy. The business serves health care and industrial customers worldwide. SHINE is based in Janesville, Wisconsin, with an office in Alkmaar, Netherlands.
SHINE
Series B in 2018
SHINE develops and deploys fusion-based technology to produce medical isotopes and neutron sources. Its processes generate molybdenum-99, a precursor to technetium-99m used in diagnostic imaging, and lutetium-177 for diagnostic and therapeutic use, along with iodine-131 and iodine-125 for thyroid treatment and brachytherapy, and xenon-133 for lung and brain imaging. The company’s systems also provide neutron sources for industrial imaging, radiation-effects testing, and fusion materials research. In addition to medical isotopes, SHINE aims to recycle nuclear waste and advance fusion power as a source of clean energy. The business serves health care and industrial customers worldwide. SHINE is based in Janesville, Wisconsin, with an office in Alkmaar, Netherlands.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.